Skip to main content
Message Font: Serif | Sans-Serif
No. of Recommendations: 0
Well, it is time to stop talking about CNS as a stand alone company. GlaxoSmithKline wants to buy CNS:

The offer is $37.50 -- a hefty 31% premium to Friday's close.

Should you sell now? I have not heard the conference call so I would wait for that. If CNS management says OK to this deal, there is only $.50 on the table between now and the merger. Why cap your capital gains when you could move on? But, if the CNS management says that they want to look and see if anyone else wants to buy, I'd hold. Consumer product companies that are small and doing well, as CNS is, are rare. There might be a bidding war for this company.

Just one person's opinion...

Print the post  


What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.